S1704 Impact of Rifaximin Use on Overt Hepatic Encephalopathy (OHE) Rehospitalizations Post-Discharge From an OHE Hospitalization in Commercially and Medicare-Insured Patients
Bibliographic record
Abstract
Introduction: Overt hepatic encephalopathy (OHE) is a life-threatening neurologic complication of cirrhosis with a large medical resource burden. Patients with OHE often experience recurring episodes that require rehospitalization, further adding to patient morbidity. Therefore, it is imperative to better understand the impact of post-discharge rifaximin use on OHE rehospitalizations in patients with OHE in the US. Methods: Claims data from Komodo Research Dataset (1/2016 - 9/2023) were used to identify commercial and Medicare patients with an initial OHE hospitalization. Separately for each insurance sample, patients were classified into 2 mutually exclusive cohorts based on treatment received within 30 days of index hospitalization discharge: rifaximin (± lactulose) cohort or no rifaximin cohort. The impact of rifaximin use on 30-day OHE rehospitalization risk and annual OHE hospitalization rates was compared between cohorts (adjusted for patient characteristics). Results: In the commercial sample, 6,309 and 4,381 patients were included in the rifaximin and no rifaximin cohorts, respectively. Mean age was 54.5 (rifaximin) and 53.7 (no rifaximin) years; 39.5% and 44.6% were female. In each cohort, 584 (9.3%; rifaximin) and 326 (7.4%; no rifaximin) patients had Model for end-stage liver disease-Sodium (MELD-Na) scores, with a mean score of 17.3 and 17.1, respectively. After an initial OHE hospitalization, the 30-day OHE rehospitalization risk (11.1 vs 7.0%; adjusted odds ratio [OR] 1.66; Figure 1A) and annual OHE hospitalization rate (1.26 vs 0.81; adjusted incidence rate ratio [IRR] 1.56, both P < 0.01; Figure 1B) were higher for the no rifaximin vs rifaximin cohort. In the Medicare sample, 2,779 and 3,713 patients were included in the rifaximin (89.3% Medicare Advantage) and no rifaximin cohorts (92.6% Medicare Advantage), respectively. Mean age was 67.7 (rifaximin) and 69.3 (no rifaximin) years; 49.8% and 47.9% were female. In each cohort, 434 (15.6%; rifaximin) and 414 (11.2%; no rifaximin) patients had MELD-Na scores, with a mean score of 15.1 and 14.4, respectively. After an initial OHE hospitalization, the 30-day OHE rehospitalization risk (11.7 vs 7.0%; adjusted OR 1.78; Figure 1C) and annual OHE hospitalization rate (1.38 vs 0.84; adjusted IRR 1.63, both P < 0.01; Figure 1D) were higher for the no rifaximin vs rifaximin cohort. Conclusion: Timely initiation of rifaximin post-discharge was associated with reduced risk of 30-day rehospitalization and lower annualized rehospitalization rates in both commercially and Medicare insured patients.Figure 1.: Comparison between the rifaximin and no rifaximin cohorts of (A) 30-day risk of OHE rehospitalization and (B) annual OHE hospitalization rate in the commercial sample and (C) 30-day risk of OHE rehospitalization and (D) annual OHE hospitalization rate in the Medicare sample. *Significant at the 5% level. IRR: incidence rate ratio; OHE: overt hepatic encephalopathy; OR: odds ratio.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.006 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".